trial

Response Shift and Quality of Life in Patients Suffering From Schizophrenia and Their Caregivers

NCTId NCT02868307
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 200 (actual)
Sponsored by Assistance Publique Hopitaux De Marseille
Primary completion 2016-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
200 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2012-07
Primary completion
2016-01
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Answering questionnaire

Sponsors

Assistance Publique Hopitaux De MarseilleLead Sponsor

Investigators

2
Urielle DESALBRESStudy Director
Laurent BOYER, MDPrincipal Investigator

Sites

1 total
Marseille, France

Facts & assertions

4 sourced
Enrollment
200
Phase
NA
Primary Completion Date
2016-01
Status
UNKNOWN
relationships
The graph out of here
drug
Answering questionnaire
drug
lead_sponsor
Assistance Publique Hopitaux De Marseille
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Urielle DESALBRES
person
Laurent BOYER, MD
person